28 July 2026 - Bausch Health announces that Elidel (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients.

Elidel cream is indicated for second-line therapy for short-term and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients 3 months of age and older, in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies.

Read Bausch Health press release